HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Staal-Schreinemachers, A. L. Articles by Lakke, J. P.W.F. Search for Related Content PubMed PubMed Citation Articles by Staal-Schreinemachers, A. L. Articles by Lakke, J. P.W.F.

Low-dose bromocriptine therapy in Parkinson's disease

Double-blind, placebo-controlled study

Department of Neurology, University Hospital, Groningen, The Netherlands.

Twenty-one de novo parkinsonian patients in stage I to III of the Hoehn and Yahr scale completed a 6-month, double-blind, placebo-controlled study. Low-dose bromocriptine (15 mg daily) was effective. Rigidity improved more than tremor or bradykinesia. Sustained satisfactory benefit was seen only in patients with mild Parkinson's disease.

Address correspondence and reprint requests to Dr. Staal-Schreinemachers, University Hospital, Department of Neurology, Oostersingel 59, 9713 EZ Groningen, The Netherlands.

Accepted for publication June 19, 1985.

This article has been cited by other articles:

				R. Kurlan International Symposium on Early Dopamine Agonist Therapy of Parkinson's Disease Arch Neurol, February 1, 1988; 45(2): 204 - 208. [Abstract] [PDF]